



**Title 21 Vacancy Announcement**  
**U.S. Department of Health and Human Services (HHS)**  
**Food and Drug Administration (FDA)**  
**Center for Drug Evaluation and Research (CDER)**  
**Office of New Drugs (OND)**  
**Office of Drug Evaluation Science (ODES)**  
**Division of Biomedical Informatics, Research & Biomarkers Development (DBIRBD)**

**Application Period:** July 24, 2023 - August 4, 2023

**Area of Consideration:** United States Citizenship is required. You must be a U.S. Citizen or U.S. National. Foreign nationals or legal permanent residents are not eligible for consideration.

**Position:** Division Director (Supervisory Physician)

**Series:** AD-0602

**Location(s):** Silver Spring, Maryland

**Salary:** Starting at \$165,000

**Work Schedule:** Full Time

**Cures Band(s):** Band F

**Full Performance Band Level:** Band F

**Travel Requirements:** 25% or less

**Bargaining Unit:** 8888

**Relocation Expenses Reimbursement:** You may qualify for reimbursement of relocation expenses in accordance with agency policy.

**This position is being filled under a stream-lined hiring authority, Title 21, Section 3072 of the 21st Century Cures Act. The candidate selected for this position will serve under a career or career-conditional appointment and be paid under the provisions of this authority.**

**Additional information on 21st Century Cures Act can be found here:**

[21st Century Cures Act Information](#)

## Introduction

The Food and Drug Administration (FDA) is the regulatory, scientific, public health and consumer protection agency responsible for ensuring all human and animal drugs, medical devices, cosmetics, foods, food additives, drugs and medicated feeds for food producing animals, tobacco and radiation emitting devices safe, and effective.

The mission of the Center for Drug Evaluation and Research (CDER) is to perform an essential

public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. CDER regulates over-the-counter (OTC) and prescription drugs, including biological therapeutics and generic drugs.

Office of New Drugs (OND) develops and implements the Center's review management and scientific policies, including user fee policies, pertaining to the drug review process. OND also reviews Investigational New Drug (IND) applications for all classes of drug and therapeutic products for human use with the exception of generic drug applications and recommends appropriate action with respect to safety and effectiveness of clinical trials.

In addition, OND evaluates for safety and effectiveness and approves New Drug Applications (NDAs) for drug products and Biological License Applications (BLAs) for human use.

Office of Drug Evaluation Science (ODES) supports Office of New Drug's (OND) mission to foster advances in drug development by providing focused scientific expertise on the development and implementation of novel drug development tools, including clinical outcome assessments, and biomarkers. ODES also supports OND's patient focused drug development activities to incorporate the patient's voice in drug development. The office facilitates the development of tools and practices for the robust analysis and interpretation of data to support clinical assessment and decision-making. In addition, ODES is responsible for OND's research portfolio management to promote advancements in regulatory science and foster drug development.

The Division of Biomedical Informatics, Research & Biomarkers Development (DBIRBD) works closely with all Office of New Drugs (OND) offices and divisions as well as CDER, Center of Biologics Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH) on cross cutting scientific review and policy initiatives concerning biomarker development and regulatory science activities. The Division oversees the Biomarkers Qualification program and the recently developed pilot program, Innovative Science and Technology Approaches for New Drugs (ISTAND), that will help expedite the development of promising therapeutics to address unmet medical needs.

## Duties/Responsibilities

As a **Division Director**, the incumbent serves in the Division of Biomedical Informatics, Research & Biomarker Development (DBIRBD) and is responsible for providing direction, oversight, and leadership to subordinate staff comprised of multidiscipline reviewers. The review teams are multidisciplinary scientific teams that review and provide consults in relation to biomarker development and regulatory science activities that affect the approvability of regulatory submissions and applications. Serves as the principal advisor to the OND Office Director and Office of Drug Evaluation Science (ODES) Directors in matters related to regulatory science activities and provides authoritative advice and guidance on all aspects of biomarker development.

The incumbent is responsible for developing standards for the review of safety databases. Other duties include but are not limited to the following:

- Enables OND clinical reviewers to make data-driven decisions that impact public health by bridging the organizations clinical and informatics expertise together to develop tools and best practices for staff analyses and interpretation of diverse data sources.
- Oversees the development, implementation, and evaluation process and policy issues related to OND's regulatory science activities, including providing authoritative advice, guidance, oversight, technical expertise, leadership, and consultative services to OND drug review divisions on critical aspects of regulatory science.
- Provides expert advice on regulatory science, including biomarker development on OND working groups related to regulatory science activities.
- Directs the development policies, procedures, and staff training necessary to implement regulatory science activities which require integrated evaluation of information to inform regulatory consistency throughout OND; including, contributing to Center-level and intra-Center level discussions and meetings on the formulation and development of policy, reporting to Congress on biomarker development and serving as the Office lead for international activities related to biomarkers.
- Provides a perspective on the broad range of drug development programs in CDER for purposes related to the objectives of the Biomarker Qualification Program (BQP); develops content and processes to harmonize biomarker development approaches between those under drug-specific programs and those through formal qualification.
- Communicates biomarker development needs and directs external outreach and communications to foster new partnerships and approaches to aid in biomarker development.

**Supervisory responsibilities:** Manages functional discipline. Supervise and evaluate staff who serve as experts in their field. Provides occupational specific technical and administrative direction and supervision 25 percent or more of the time to subordinate supervisors and staff performing the work and functions of the organizational unit. Obtains resources and identifies strategic objectives for the organization.

## Conditions of Employment

- U.S. Citizenship requirement or proof of being a U.S. National must be met by closing date.
- Employment is subject to the successful completion of a background investigation, verification of qualifications, completion of onboarding forms, submission of required documents, and any other job-related requirement before or after appointment.
- Applicants must meet all qualification requirements by the closing date of this announcement.
- Direct Deposit: You will be required to have all federal salary payments electronically deposited into a bank account with a financial institution of your choice.
- FDA participates in e-Verify: All new hires must complete the I-9 form; this information will be processed through e-Verify to determine your employment eligibility. If a discrepancy

arises, you must take affirmative steps to resolve the matter.

- Males born after December 31, 1959 must be registered with the Selective Service.
- One-year supervisory probationary period may be required.
- Financial Disclosure may be required.
- Ethics Clearance may be required.
- Background Investigation/Security Clearance is required. All employees must pass a security investigation. Failing to pass the background check may be grounds for removal or legal action. If hired, you may be subject to additional investigations at a later time.

## Qualifications

To be placed into a Cures position, candidates must meet the following criteria:

1. Scientific, Technical, and Professional Fields
2. Qualified and Outstanding Candidates
  - a. **Qualified** applies to all candidates for Cures appointments. The FDA OTS will use the basic requirements defined in the [OPM Qualification Standards](#) as a baseline for comparing experience levels and other candidate attributes for relevant positions.
  - b. **Outstanding** candidates can be defined by existing outstanding work experience, outstanding performance rating, or both.

To qualify for this Title 21 Cures position, the candidate(s) must meet the following **required** qualifications. *Please note: Additional education and experience listed that is not indicated as required is preferable and desired. Candidates who do not meet the “desired” criteria will not be excluded from consideration for this position.*

### **Education Requirement:**

#### **Physician Series, AD-0602**

For more information, please see: [OPM Occupational Series Qualification Requirements.](#)

Desired Education: N/A

### **Professional Experience:**

Our ideal candidate will possess:

- Ability to drive collaboration, empower staff, provide expert advice and consultation, coordinate program activities, and spearhead important program initiatives.
- Knowledge of leadership principles and concepts regulating and evaluating new drugs and biological products.
- Ability to manage and lead a diverse interdisciplinary staff.

Desired Professional Experience:

Our ideal candidate will possess experience in drug development programs with the development, application and assessment of biomarkers and with the application of research and bioinformatics.

## Education Transcripts

SUBMITTING YOUR TRANSCRIPTS: Positions which are scientific or technical in nature often have very specific educational requirements. A transcript is required to verify educational achievement. Pay careful attention to the Qualifications and Education sections to identify vacancies where a transcript is required. Even if you hold a similar position or are a current FDA employee, you are not exempt from transcript requirements.

FOREIGN EDUCATION: If you are using education completed in foreign colleges or universities to meet the qualification requirements, you must show that the education credentials have been evaluated by a private organization that specializes in interpretation of foreign education programs and such education has been deemed equivalent to that gained in an accredited U.S. education program; or full credit has been given for the courses at a U.S. accredited college or university. For more information about this requirement, please visit the [U.S. Department of Education website for Foreign Education Evaluation](#).

## Security Clearance Requirements

Background Investigation/Security Clearance Requirements: Non-Sensitive/High Risk

A background security investigation will be required for all appointees. Appointment will be subject to the applicant's successful completion of a background security investigation and favorable adjudication. Failure to successfully meet the requirements may be grounds for appropriate personnel action. In addition, if hired, a background security investigation or supplemental investigation may be required later.

Applicants are also advised that all information concerning qualification is subject to investigation. False representation may be grounds for non-selection and/or appropriate disciplinary action.

## Ethics Clearance Requirements

This position may require financial disclosure reporting and will be subject to FDA's prohibited financial interest regulation. If you are hired, you may be required to divest of certain financial interests. You are advised to seek additional information on this requirement from the hiring official before accepting any job offers. For more information, please visit the FDA Ethics web page: <https://www.fda.gov/about-fda/jobs-and-training-fda/ethics>.

## Equal Employment Opportunity

Equal Employment Opportunity Policy

The United States Government does not discriminate in employment on the basis of race, color,

religion, sex (including pregnancy and gender identity), national origin, political affiliation, sexual orientation, marital status, disability, genetic information, age, membership in an employee organization, retaliation, parental status, military service, or other non-merit factor. [Equal Employment Opportunity \(EEO\) for federal employees & job applicants](#)

## Reasonable Accommodation

### Reasonable Accommodation Policy

Federal agencies must provide reasonable accommodation to applicants with disabilities where appropriate. Applicants requiring reasonable accommodation for any part of the application process should follow the instructions in the job opportunity announcement. For any part of the remaining hiring process, applicants should contact the hiring agency directly. Determinations on requests for reasonable accommodation will be made on a case-by-case basis. A reasonable accommodation is any change to a job, the work environment, or the way things are usually done that enables an individual with a disability to apply for a job, perform job duties or receive equal access to job benefits.

Under the Rehabilitation Act of 1973, federal agencies must provide reasonable accommodations when: An applicant with a disability needs an accommodation to have an equal opportunity to apply for a job. An employee with a disability needs an accommodation to perform the essential job duties or to gain access to the workplace. An employee with a disability needs an accommodation to receive equal access to benefits, such as details, training, and office-sponsored events. You can request a reasonable accommodation at any time during the application or hiring process or while on the job. Requests are considered on a case-by-case basis. Learn more about [disability employment and reasonable accommodations](#) or [how to contact an agency](#).

## E-Verify

The Food and Drug Administration participates in the USCIS Electronic Employment Eligibility Verification Program (E-Verify). E-Verify helps employers determine employment eligibility of new hires and the validity of their Social Security numbers.

## How to Apply

Submit resume or curriculum vitae with cover letter by August 4, 2023 to Lisa Conrad at [ONDIORecruitment@fda.hhs.gov](mailto:ONDIORecruitment@fda.hhs.gov) . Candidate resumes may be shared with hiring officials within the CDER with a similar job vacancy. Candidates can opt out of this process by annotating resume with “do not share”.

Please reference Job Reference ID: **ODES/DBIRBD-ES-23-008** in the email subject line.

## Announcement Contact

For questions regarding this Cures position, please contact Danielle Wright at [Danielle.Wright@fda.hhs.gov](mailto:Danielle.Wright@fda.hhs.gov) .

The U.S. Department of Health and Human Services is an equal opportunity employer with a smoke free environment.

*FDA is an equal opportunity employer.*

